Patents by Inventor Marc Jacquemin
Marc Jacquemin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140163283Abstract: A method of carrying out Suzuki-Miyaura CC-coupling reactions, includes reacting an aryl halide with an aryl boronic acid in an organic solvent in the presence of an oxide supported palladium catalyst and a base, characterized in that the base is added in the form of an aqueous solution with a constant flow rate within a predetermined period of time at the beginning of the reaction.Type: ApplicationFiled: July 6, 2012Publication date: June 12, 2014Applicant: UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Eric Gaigneaux, Marc Jacquemin, Damien Hauwaert, Caroline Cellier, Alain Merschaert, Raquel Mateos Blanco
-
Publication number: 20130289321Abstract: The present invention is directed to a method of carrying out Suzuki-Miyaura CC-coupling reactions, including reacting an aryl halide with an aryl boronic acid in an organic solvent in the presence of a carbon supported palladium catalyst and a base, wherein the reactions are carried out at constant pH. The invention is also directed to a palladium on carbon catalyst suitable for catalyzing Suzuki-Miyaura CC-coupling reactions.Type: ApplicationFiled: December 22, 2011Publication date: October 31, 2013Applicant: UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Eric Gaigneaux, Marc Jacquemin, Damien Hauwaert
-
Patent number: 8293234Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: March 29, 2010Date of Patent: October 23, 2012Assignee: Life Sciences Research PartnersInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 8282923Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: March 29, 2010Date of Patent: October 9, 2012Assignee: Life Sciences Research PartnersInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 8277805Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: March 26, 2010Date of Patent: October 2, 2012Assignee: Life Sciences Research PartnersInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 8071094Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.Type: GrantFiled: July 18, 2006Date of Patent: December 6, 2011Assignee: Laboratoire Francais du Fractionement Et des BiotechnologiesInventors: Christian Behrens, Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Publication number: 20110070226Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: ApplicationFiled: March 26, 2010Publication date: March 24, 2011Inventors: Jean-Marie SAINT-REMY, Marc JACQUEMIN
-
Patent number: 7858089Abstract: The present invention relates to new antibodies and fragments and derivatives thereof. These antibodies bind to the A2 domain of Factor VIII (FVIII) of the coagulation pathway and inhibit the coagulation activity of FVIII. The antibodies are particularly suited for the characterization of the structure and function of FVIII, for the design of therapeutic strategies for eradication of FVIII inhibitors and for the use as a medicament. The invention also relates to cell lines producing the specific antibodies. The present invention furthermore relates to pharmaceutical compositions comprising the antibodies, fragments and/or derivatives of the invention and to methods of preventing and treating cardiovascular disorders by using the antibodies or fragments and derivatives thereof or pharmaceutical compositions thereof.Type: GrantFiled: July 31, 2006Date of Patent: December 28, 2010Assignee: Life Sciences Research Partners VZWInventors: Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Publication number: 20100322967Abstract: The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor.Type: ApplicationFiled: October 8, 2008Publication date: December 23, 2010Applicants: Life Sciences Research Partners VZW, VIB VZWInventors: Thierry Vandendriessche, Marinee Chuah, Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20100272715Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: ApplicationFiled: March 29, 2010Publication date: October 28, 2010Inventors: JEAN-MARIE SAINT-REMY, MARC JACQUEMIN
-
Publication number: 20100266586Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: ApplicationFiled: March 29, 2010Publication date: October 21, 2010Inventors: Jean-Marie SAINT-REMY, Marc Jacquemin
-
Patent number: 7785594Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: August 16, 2004Date of Patent: August 31, 2010Assignee: Life Sciences Research Partners VZWInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 7595052Abstract: The present invention is related to a method for modulating the immune system of a mammal patient towards an allergen, which comprises the step of inducing a pre-sensitisation of the immune system of said patient towards an immunogen carrying at least one T cell epitope homologous and functionally similar to an epitope present on said allergen and deriving from a naturally-occurring antigen in order to modify the response of said patient to a further sensitisation to said allergen, allowing that the immune response towards the allergen is modulated and that no allergy towards said allergen will be developed in said patient.Type: GrantFiled: March 16, 2001Date of Patent: September 29, 2009Assignee: Collen Research FoundationInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20080206254Abstract: The present invention relates to new antibodies and fragments and derivatives thereof, which are particularly suited for the characterization of the structure and function of Factor VIII (FVIII) of the coagulation pathway, for the design of therapeutic strategies for eradication of FVIII inhibitors and for the use as a medicament The invention also relates to cell lines producing the specific antibodies. The present invention furthermore relates to pharmaceutical compositions comprising the antibodies, fragments and/or derivatives of the Invention and to methods of preventing and treating cardiovascular disorders by using the antibodies or fragments and derivatives thereof or pharmaceutical compositions thereof.Type: ApplicationFiled: July 31, 2006Publication date: August 28, 2008Applicant: Life Sciences Research Partners vzwInventors: Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Publication number: 20070065425Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.Type: ApplicationFiled: July 18, 2006Publication date: March 22, 2007Applicant: Laboratoire Francais Du Fractionnement Et Des BiotechnologiesInventors: Christian Behrens, Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Publication number: 20060292149Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: ApplicationFiled: August 16, 2004Publication date: December 28, 2006Applicant: D. COLLEN RESEARCH FOUNDATION VZWInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20060239998Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.Type: ApplicationFiled: July 28, 2003Publication date: October 26, 2006Applicant: D. COLLEN RESEARCH FOUNDATION VZWInventors: Jean Guy Gilles, Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 7122380Abstract: A pharmaceutical composition suitable for administration to human beings in the prevention or treatment of immunologic disorders includes: an immune complex of an antigen and a purified antibody specific thereto, the antigen being selected from a group consisting of antigens that cause pathogenic immunologic reactions in autoimmune disease and graft rejections, and the antigen and antibody being present in a ratio whereby the antibody blocks essentially all binding sites of the antigen; and a pharmacologically acceptable carrier or diluent. The invention also provides a method of administering the composition for treatment of autoimmune disease and treatment or prevention of graft rejections.Type: GrantFiled: May 13, 1994Date of Patent: October 17, 2006Assignee: International Institute of Cellular and Molecular PathologyInventors: Marc Jacquemin, Jean-Marie St. Remy, Philippe Lebrun, Serge Lebecque, Piere Masson
-
Publication number: 20060115474Abstract: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.Type: ApplicationFiled: December 9, 2005Publication date: June 1, 2006Inventors: Marc Jacquemin, Jean-Marie Saint-Remy
-
Publication number: 20030152581Abstract: The present invention is related to a compound for the prevention and/or the treatment of allergy consisting of:Type: ApplicationFiled: September 10, 2002Publication date: August 14, 2003Inventors: Jean-Marie Saint-Remy, Marc Jacquemin